
浏览全部资源
扫码关注微信
1. 复旦大学附属肿瘤医院核医学科,复旦大学上海医学院肿瘤学系,上海 200032
2. 复旦大学生物医学影像研究中心,上海 200032
3. 上海分子影像探针工程技术研究中心,上海 200032
4. 上海市质子重离子医院核医学科,上海 201315
5. 复旦大学核物理与离子束应用教育部重点实验室,上海 200433
[ "杨梓怡(ORCID: 0000-0002-8947-2623),住院医师。" ]
宋少莉(ORCID: 0000-0003-2544-7522),主任医师。
收稿:2023-05-30,
修回:2023-09-05,
纸质出版:2023-09-30
移动端阅览
杨梓怡, 顾丙新, 许晓平, 等. 18F-FDG和68Ga-FAPI PET/CT在不同恶性肿瘤肺转移诊断中的对比研究[J]. 中国癌症杂志, 2023,33(9):829-833.
Ziyi YANG, Bingxin GU, Xiaoping XU, et al. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in the diagnosis of lung metastasis in different malignant tumors[J]. China Oncology, 2023, 33(9): 829-833.
杨梓怡, 顾丙新, 许晓平, 等. 18F-FDG和68Ga-FAPI PET/CT在不同恶性肿瘤肺转移诊断中的对比研究[J]. 中国癌症杂志, 2023,33(9):829-833. DOI: 10.19401/j.cnki.1007-3639.2023.09.003.
Ziyi YANG, Bingxin GU, Xiaoping XU, et al. Comparison of 18F-FDG and 68Ga-FAPI PET/CT in the diagnosis of lung metastasis in different malignant tumors[J]. China Oncology, 2023, 33(9): 829-833. DOI: 10.19401/j.cnki.1007-3639.2023.09.003.
背景与目的:
18
F-氟代脱氧葡萄糖(
18
F-flurodeoxyglucose,
18
F-FDG)正电子发射计算机体层成像(positron emission tomography and computed tomography,PET/CT)是诊断恶性肿瘤伴远处转移的常用方法,但对肺部转移灶尤其是小病灶的检测仍不理想。
68
Ga-成纤维细胞激活蛋白抑制剂(
68
Ga-labeled fibroblast activation protein inhibitors,
68
Ga-FAPI)已被用于靶向成纤维细胞激活蛋白和肿瘤基质的可视化。
68
Ga-FAPI PET/CT对大多数癌症的原发灶及其转移灶的诊断价值均高于
18
F-FDG,但至今尚未见到对恶性肿瘤肺部转移性病变的对比研究。因此,本研究旨在探讨
18
F-FDG和
68
Ga-FAPI PET/CT对不同恶性肿瘤肺转移病变的诊断价值。
方法:
回顾性分析复旦大学附属肿瘤医院2020年5月—2022年3月于1周内行
18
F-FDG和
68
Ga-FAPI PET/CT检查的20例恶性肿瘤肺转移患者的临床、病理学及影像学资料,其中上皮源性恶性肿瘤(癌)11例,间叶
源性恶性肿瘤(肉瘤)9例。采用配对
t
检验比较
68
Ga-FAPI和
18
F-FDG的病灶最大标准摄取值(maximum standard uptake value,SUV
max
)和肿瘤与本底比值(target-to-background ratio,TBR)参数之间的差异;采用线性相关性分析SUV
max
和TBR与肺转移灶短径之间的相关性。
结果:
20例患者共81个肺转移灶(51个来自癌转移,30个来自肉瘤转移),
18
F-FDG检出阳性病灶72个,
68
Ga-FAPI检查阳性病灶70个。与
68
Ga-FAPI相比,肺转移灶
18
F-FDG摄取值更高,尤其是癌来源的肺转移病灶(
P
<
0.001)。线性相关性分析结果显示,两种显像探针的半定量代谢参数值与肺转移病灶短径之间呈正相关(
P
<
0.001)。
结论:
68
Ga-FAPI在检测恶性肿瘤肺转移病变时并无明显优势,尤其是在上皮组织来源的恶性肿瘤肺转移诊断中,
18
F-FDG摄取值往往更高。
Background and purpose:
18
F-flurodeoxyglucose (
18
F-FDG) positron emission tomography and computed tomography (PET/CT) is a common method for the diagnosis of malignant tumors with distant metastases. However the detection of lung metastases
especially small lesions
is still unsatisfactory.
68
Ga-labeled fibroblast activation protein inhibitors (
68
Ga-FAPI) have been used to target fibroblast activating proteins and visualize tumor stroma. The diagnostic value of
68
Ga-FAPI PET/CT is higher than that of
18
F-FDG in the primary sites and metastases of most cancers
but no comparative study has been seen in lung metastases of malignant tumors. Therefore
this study aimed to investigate the diagnostic value of
18
F-FDG and
68
Ga-FAPI PET/CT in different malignant lung metastases.
Methods:
The clinical
pathological and imaging data of 20 patients with lung metastasis who underwent
18
F-FDG and
68
Ga-FAPI PET/CT examination within one week in Fudan University Shanghai Cancer Center from May 2020 to March 2022 were retrospectively analyzed. Among them
11 cases were epithelial malignant tumors (carcinoma)
and 9 cases were mesophyll malignant tumors (sarcoma). The semi-quantitative metabolic parameters inclu
ding maximum standard uptake value (SUV
max
) and target-to-background ratio (TBR) of
68
Ga-FAPI and
18
F-FDG were compared by paired t test. The linear correlation between SUV
max
and TBR and the short diameter of lung metastasis were analyzed.
Results:
A total of 81 lung metastases (51 carcinomas and 30 sarcomas) were detected in 20 patients
72 positive lesions were detected by
18
F-FDG and 70 positive lesions by
68
Ga-FAPI. Compared with
68
Ga-FAPI
18
F-FDG uptake was higher in lung metastases
especially those of carcinoma (
P
<
0.001). The results of linear correlation analysis showed that the semi-quantitative metabolic parameters of the two imaging probes were positively correlated with the short diameter of lung metastases (
P
<
0.001).
Conclusion:
68
Ga-FAPI has no obvious advantage in the detection of lung metastases from malignant tumors. Especially in the diagnosis of lung metastases from epithelial tissues
the uptake of
18
F-FDG tends to be higher.
张建波 , 宋魏 , 王媛媛 , 等 . 肺转移性肿瘤113例临床病理学观察 [J ] . 心肺血管病杂志 , 2017 , 36 ( 12 ): 979 - 982 , 987.
ZHANG J , SONG W , WANG Y , et al . Clicical and pathological analysis of 113 cases of lung metastatic tumors [J ] . J Cardiovasc Pulm Dis , 2017 , 36 ( 12 ): 979 - 982 , 987.
ROHREN E M , TURKINGTON T G , COLEMAN R E . Clinical applications of PET in oncology [J ] . Radiology , 2004 , 231 ( 2 ): 305 - 332 . DOI: 10.1148/radiol.2312021185 http://doi.org/10.1148/radiol.2312021185
IAGARU A , CHAWLA S , MENENDEZ L , et al . 18 F-FDG PET and PET/CT for detection of pulmonary metastases from musculoskeletal sarcomas [J ] . Nucl Med Commun , 2006 , 27 ( 10 ): 795 - 802 . DOI: 10.1097/01.mnm.0000237986.31597.86 http://doi.org/10.1097/01.mnm.0000237986.31597.86
魏昊 , 兰晓莉 , 廖姗珊 , 等 . 18 F-FDG PET/CT显像评价胃癌肺转移 [J ] . 华中科技大学学报(医学版) , 2016 , 45 ( 2 ): 141 - 144 .
WEI H , LAN X , LIAO S , et al . Evaluation of lung metastasis in gastric cancer with 18 F-FDG PET/CT imaging [J ] . Acta Med Univ Sci Technol Huazhong , 2016 , 45 ( 02 ): 141 - 144 .
HATHI D K , JONES E F . 68 Ga FAPI PET/CT: tracer uptake in 28 different kinds of cancer [J ] . Radiol Imaging Cancer , 2019 , 1 ( 1 ): e194003 . DOI: 10.1148/rycan.2019194003 http://doi.org/10.1148/rycan.2019194003 http://pubs.rsna.org/doi/10.1148/rycan.2019194003 http://pubs.rsna.org/doi/10.1148/rycan.2019194003
LINDNER T , LOKTEV A , ALTMANN A , et al . Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein [J ] . J Nucl Med, 20 18 , 59 ( 9 ): 1415 - 1422 .
CHEN H , ZHAO L , RUAN D , et al . Usefulness of[ 68 Ga ] Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [ 18 F ] FDG PET/CT findings [J ] . Eur J Nucl Med Mol Imaging , 2021 , 48 ( 1 ): 73 - 86 . DOI: 10.1007/s00259-020-04940-6 http://doi.org/10.1007/s00259-020-04940-6
KOERBER S A , STAUDINGER F , KRATOCHWIL C , et al . The role of 68 Ga-FAPI PET/CT for patients with malignancies of the lower gastrointestinal tract: first clinical experience [J ] . J Nucl Med , 2020 , 61 ( 9 ): 1331 - 1336 . DOI: 10.2967/jnumed.119.237016 http://doi.org/10.2967/jnumed.119.237016 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.237016 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.119.237016
CHEN H J , PANG Y Z , WU J X , et al . Comparison of [ 68 Ga ] Ga-DOTA-FAPI-04 and [ 18 F ] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer [J ] . Eur J Nucl Med Mol Imaging , 2020 , 47 ( 8 ): 1820 - 1832 . DOI: 10.1007/s00259-020-04769-z http://doi.org/10.1007/s00259-020-04769-z
PANG Y Z , ZHAO L , LUO Z M , et al . Comparison of 68 Ga-FAPI and 18 F-FDG uptake in gastric, duodenal, and colorectal cancers [J ] . Radiology , 2021 , 298 ( 2 ): 393 - 402 . DOI: 10.1148/radiol.2020203275 http://doi.org/10.1148/radiol.2020203275 http://pubs.rsna.org/doi/10.1148/radiol.2020203275 http://pubs.rsna.org/doi/10.1148/radiol.2020203275
DING F , HUANG C , LIANG C , et al . 68 Ga-FAPI-04 vs 18 F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer [J ] . Eur J Nucl Med Mol Imaging , 2021 , 49 ( 1 ): 290 - 300 . DOI: 10.1007/s00259-021-05442-9 http://doi.org/10.1007/s00259-021-05442-9
GIESEL F L , KRATOCHWIL C , LINDNER T , et al . 68 Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents in patients with various cancers [J ] . J Nucl Med , 2019 , 60 ( 3 ): 386 - 392 . DOI: 10.2967/jnumed.118.215913 http://doi.org/10.2967/jnumed.118.215913 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.215913 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.118.215913
谢昭娟 , 全志永 , 赵小虎 , 等 . 胰腺癌摄取 68 Ga-FAPI-04的PDX动物模型及临床PET/CT显像研究 [J ] . 中华核医学与分子影像杂志 , 2021 , 41 ( 12 ): 722 - 726 .
XIE Z , QUAN Y , ZHAO X , et al . Uptake of 68 Ga-FAPI-04 in pancreatic cancer-PDX animal model and its clinical PET/CT imaging [J ] . Chin J Nucl Med Mol Imaging , 2021 , 41 ( 12 ): 722 - 726 .
CHEN R H , ZHOU X , LIU J J , et al . Relationship between 18 F-FDG PET/CT findings and HER2 expression in gastric cancer [J ] . J Nucl Med , 2016 , 57 ( 7 ): 1040 - 1044 . DOI: 10.2967/jnumed.115.171165 http://doi.org/10.2967/jnumed.115.171165 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.171165 http://jnm.snmjournals.org/lookup/doi/10.2967/jnumed.115.171165
YANG Z , LIU S , SUN Y , et al . 18 F-FDG PET/CT metabolic parameters and HER2 expression in colorectal cancer [J ] . Neoplasma , 2021 , 68 ( 4 ): 875 - 881 . DOI: 10.4149/neo_2021_200803N807 http://doi.org/10.4149/neo_2021_200803N807 http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7218&category_id=172&option=com_virtuemart http://www.elis.sk/index.php?page=shop.product_details&flypage=flypage.tpl&product_id=7218&category_id=172&option=com_virtuemart
0
浏览量
2582
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621